Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

被引：0
|
作者：
Qaisar, Aitzaz
Venugopal, Balaji
Ansel, Sonam
Jones, Robert J.
Slater, Sarah
Symeonides, Stefan N.
Malik, Jahangeer
Sundaramurthy, Aravindhan
Elliott, Tony
Devasar, Abeera
Stares, Mark
Randhawa, Manreet
机构：
[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[4] Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland
[5] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[6] NHS Lothian, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
716
引用
收藏
页数：1
相关论文
共 50 条
  • [41] C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy
    Shibata, Y.
    Kato, T.
    Shimokawaji, T.
    Yamada, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S698 - S698
  • [42] Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
    T. Anders Olsen
    Dylan J. Martini
    Sean T. Evans
    Jamie M. Goldman
    Mehmet Asim Bilen
    Journal of Medical Case Reports, 15
  • [43] AXITINIB (AXI) AND BEST SUPPORTIVE CARE (BSC) IN THE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS OF A SIMULATED TREATMENT COMPARISON (STC) ANALYSES
    Proskorovsky, I
    Benedict, A.
    Larkin, J. M. G.
    Sandin, R.
    Chen, C.
    VALUE IN HEALTH, 2012, 15 (07) : A410 - A410
  • [44] LEVOTHYROXIN TREATMENT OF HYPOTHYROIDISM AND AXITINIB (AG-013736) EFFICACY IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Dutcher, J. P.
    Rixe, O.
    Motzer, R. J.
    Wilding, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Rosbrook, B.
    Rini, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [45] Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib
    Fujita, Tetsuo
    Nishi, Morihiro
    Tabata, Ken-ichi
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    Iwamura, Masatsugu
    ANTI-CANCER DRUGS, 2016, 27 (10) : 1028 - 1032
  • [46] PREDICTIVE VALUE OF TIME TO BEST RESPONSE FOR EFFICACY MTOR INHIBITORS (MTORI) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS)
    Elaidi, R. T.
    Teghom, C.
    Comte, A.
    Jebali, M.
    Fouque, J.
    Medioni, J.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 282 - 282
  • [47] Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    Escudier, Bernard
    Hariharan, Subramanian
    Roberts, W. Gregory
    Tarazi, Jamal
    Rosbrook, Brad
    Askeroya, Zena
    DeAnnuntis, Liza L.
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (06) : 540 - 547
  • [48] Looking for predictive biomarkers for sunitinib in metastatic renal clear cell carcinoma (mRCC)
    Maroto, P.
    Esteban, E.
    Méndez-Vidal, M. J.
    Fernandez-Parra, E. M.
    Leon, L.
    Perez-Valderrama, B.
    Domenech, M.
    Calderero, V.
    Perez-Gracia, J. L.
    Algaba, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S676 - S676
  • [49] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S521 - S521
  • [50] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 60 - 60
12345